DelveInsight’s “Chronic Myelocytic Leukemia (CML) Market Insights, Epidemiology, and Market Forecast-2032" report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Chronic Myelocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key facts of the Chronic Myelocytic Leukemia Market:
- According to an estimate by the American Cancer Society in 2019, Chronic Myelocytic Leukemia accounts for 10-50 per cent of all leukaemia cases and about 1 in 526 are likely to be affected by it.
- In 2021, an estimated 9,110 people (5,150 men and 3,960 women) in the United States were diagnosed with Chronic Myelocytic Leukemia. About 50% of cases are found in people older than 64.
Key benefits of the Chronic Myelocytic Leukemia Market report:
- The study provides a detailed review of Chronic Myelocytic Leukemia, including its causes, signs and symptoms, pathophysiology, diagnosis, and current treatments.
- Study of the 7MM has offered comprehensive insight into the epidemiology and management of Chronic Myelocytic Leukemia.
- Furthermore, an all-inclusive description of both present and emerging Chronic Myelocytic Leukemia treatments is offered, as well as an analysis of future therapies that will have an influence on the current treatment landscape.
- The research includes a full evaluation of the Chronic Myelocytic Leukemia market, both historical and anticipated, as well as drug outreach in the 7MM population.
- By understanding the trends defining and driving the worldwide Chronic Myelocytic Leukemia market, the study gives you an advantage when formulating business plans.
Chronic Myelocytic Leukemia Overview
Chronic myelogenous leukemia (CML) is a rare type of cancer of the bone marrow. Chronic myelogenous leukemia causes an increased number of white blood cells in the blood. This cancer tends to progress more slowly than acute forms of leukemia. Chronic myelogenous leukemia can also be called chronic myeloid leukemia and chronic granulocytic leukemia. It typically affects older adults and rarely occurs in children, though it can occur at any age. Chronic myelogenous leukemia often doesn't cause signs and symptoms. However, when they occur, signs and symptoms may include:
- Bone pain
- Easy bleeding
- Feeling full after eating a small amount of food
- Feeling run-down or tired
- Fever
- Weight loss without trying
- Loss of appetite
- Pain or fullness below the ribs on the left side
- Night sweats
Chronic myelogenous leukemia occurs when something goes awry in the genes of your bone marrow cells.
Chronic Myelocytic Leukemia Market
The report's Chronic Myelocytic Leukemia market outlook assists in developing a detailed understanding of historic, current, and forecasted Chronic Myelocytic Leukemia market trends by analyzing the impact of current Chronic Myelocytic Leukemia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This section examines the Chronic Myelocytic Leukemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing market need, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, market impact, and key opinion leaders' perspectives. Chronic Myelocytic Leukemia market statistics are supplied with pertinent tables and graphs to provide a comprehensive picture of the market at a glance.
According to DelveInsight, the Chronic Myelocytic Leukemia market in 7MM is expected to undergo significant change between 2019 and 2032.
Know more about the pipeline therapies and recent developments @ Chronic Myelocytic Leukemia Pipeline Report
Chronic Myelocytic Leukemia Companies
- Ascentage Pharma Group Inc.
- HealthQuest Pharma Inc.
- Astex Pharmaceuticals, Inc.
- Eisai Inc.
- Pfizer
- Teva Branded Pharmaceutical Products R&D, Inc.
- Cephalon
- ChemGenex Pharmaceuticals, and Many More
Chronic Myelocytic Leukemia Pipeline
- HQP1351
- Decitabine
- Bosutinib
- Imatinib
- Omacetaxine mepesuccinate
Table of Contents
1. Key Insights
2. Executive Summary of Chronic Myelocytic Leukemia (CML)
3. Competitive Intelligence Analysis for Chronic Myelocytic Leukemia (CML)
4. Chronic Myelocytic Leukemia (CML): Market Overview at a Glance
5. Chronic Myelocytic Leukemia (CML): Disease Background and Overview
6. Patient Journey
7. Chronic Myelocytic Leukemia (CML) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Myelocytic Leukemia (CML) Unmet Needs
10. Key Endpoints of Chronic Myelocytic Leukemia (CML) Treatment
11. Chronic Myelocytic Leukemia (CML) Marketed Products
12. Chronic Myelocytic Leukemia (CML) Emerging Therapies
13. Chronic Myelocytic Leukemia (CML): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Chronic Myelocytic Leukemia (CML)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
